Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

131I tositumomab.

C R Culy¹, H M Lamb

¹Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy

|November 24, 2007

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Cladribine: a review of its use in multiple sclerosis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007

Same author

Mizolastine: a review of its use in allergic rhinitis and chronic idiopathic urticaria.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007

Same author

Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007

Same author

Denileukin diftitox.

American journal of clinical dermatology·2001

Same author

Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus.

Drugs·2001

Same author

Ondansetron: a review of its use as an antiemetic in children.

Paediatric drugs·2001

Same journal

Correction: Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026

Same journal

Gene Therapy Strategies for Uveal Melanoma: Adeno-associated Virus Delivery Challenges and Translational Opportunities.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026

Same journal

Review of Quality Attributes and Analytical Methods Used for Comparative Analytical Assessment of Monoclonal Antibodies as Part of Successful Biosimilar Approvals in the United States and European Union.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026

Same journal

Impact of Repeated Antigen Exposure on Humoral Tolerance: Antidrug Antibodies After Single-Dose Versus Multi-dose Adalimumab.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026

Same journal

An Overview and Trend Analysis of Biosimilar Approvals in China.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026

Same journal

Monoclonal Antibodies Targeting Bacterial Infections: A Broad Review of the Field.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026

See all related articles

Iodine-131 tositumomab, an anti-CD20 antibody, shows significant anti-cancer activity in non-Hodgkin

Area of Science:

Oncology
Immunology
Radiopharmaceutical Therapy

Background:

Non-Hodgkin's lymphoma (NHL) is a significant hematologic malignancy.
Targeted therapies like monoclonal antibodies offer new treatment avenues.
CD20 antigen is a validated target on B lymphocytes in NHL.

Purpose of the Study:

To evaluate the efficacy and safety of iodine-131 tositumomab for non-Hodgkin's lymphoma.
To assess response rates and durability in relapsed/refractory and previously untreated NHL.
To analyze outcomes when combined with other treatment modalities.

Main Methods:

Clinical trials involving iodine-131 tositumomab monotherapy and combination regimens.
Assessment of objective response rates (ORR), complete response rates (CR), and duration of response.

Related Experiment Videos

Evaluation of dose-limiting toxicities, primarily myelosuppression, and other adverse events.

Main Results:

Monotherapy achieved ORR >60% in relapsed/refractory NHL, with 62% response to retreatment.
Higher response rates and longer durations of response compared to prior chemotherapy.
High-dose combination with stem cell transplant yielded 86% ORR; 100% ORR in untreated NHL with fludarabine combination.

Conclusions:

Iodine-131 tositumomab demonstrates significant efficacy in various NHL settings.
It offers improved outcomes compared to conventional chemotherapy in relapsed/refractory disease.
Reversible myelosuppression is the dose-limiting toxicity, manageable in most cases.